AbbVie Inc. · 2026 Q2

Consensus vs reported

QoQ and YoY are measured on the same basis as each panel's own consensus, so no panel compares two different measures.

2026 Q2 preview

Reported this quarter

Each tile opens the full quarterly series. Download the numbers as CSV or JSON.

What we learned

1. A six-cent EPS miss cost nearly 5% of the company. Adjusted EPS of $3.65 against $3.71 , on revenue of $16.99B that beat a $16.77B estimate by 1.3%. The market priced the smaller of the two numbers.
2. The guidance cut is disclosed spending, not deceleration. Full-year adjusted EPS went to $13.87–14.07 from $13.91–14.11, carrying $0.14 of Apogee dilution on a ~$10.9B deal closing in Q3 and $0.58 of year-to-date acquired IPR&D and milestone expense .
3. The post-Humira thesis is landing close to its best case. Skyrizi $5.505B, +24.4% ; Rinvoq $2.525B, +24.5% — two-plus years past the cliff and still growing in the mid-twenties, with immunology as a whole at $8.786B, +15.1%.
4. Humira's decline is now the small number. Down 35.9% to $756 million — less than a seventh of Skyrizi alone. The patent cliff that defined AbbVie's last five years no longer moves the quarter.
5. Neuroscience is the underrated line and oncology is the soft one. Neuroscience grew 20.3% to $3.228B ; oncology fell 1.5% to $1.650B as Imbruvica's −29.4% outran Venclexta's +11.6%.

Read the full analysis: AbbVie Q2 2026: Skyrizi and Rinvoq Keep Compounding — Stock Falls on a Narrow EPS Miss →

Coverage around this release

Estimate against reported

Estimates are the consensus we published on our own preview for that quarter; quarters we did not preview carry the reported figure only. Where a consensus was set on a non-GAAP basis, the reported column shows that same measure.

Sources & downloads

2026 Q2 across the sector

Every ABBV quarter